|
2025
|
G/S
|
Pharmaceutical preparations for the treatment of angioedema;
pharmaceutical preparations for the... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the ... |
|
|
G/S
|
Administration of medical insurance claims; business administration and management of medication ... |
|
|
G/S
|
Administration of medical insurance claims; business administration of medication reimbursement p... |
|
|
Invention
|
Oral sebetralstat for the treatment of an attack of hereditary angioedema. The present invention ... |
|
|
Invention
|
Methods for determining amidolytic activity. The present invention provides methods relating to p... |
|
2024
|
Invention
|
Solid forms of an enzyme inhibitor and salts thereof. New solid forms of the Factor XIIa (FXIIa) ... |
|
|
Invention
|
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors.
The present inve... |
|
|
Invention
|
New solid form of a plasma kallikrein inhibitor. The invention provides a new polymorph of N-[(3-... |
|
2023
|
Invention
|
3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors. ... |
|
|
Invention
|
2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors. The present in... |
|
|
Invention
|
Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1... |
|
|
Invention
|
Formulations of a plasma kallikrein inhibitor.
The present invention provides pharmaceutical dos... |
|
|
Invention
|
Formulations of a plasma kallikrein inhibitor. The present invention provides pharmaceutical dosa... |
|
|
Invention
|
Enzyme inhibitors.
The present invention provides compounds of formula (I):
The present invent... |
|
2022
|
G/S
|
Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the ... |
|
|
Invention
|
Treatments of hereditary angioedema. The present invention relates to treatments of hereditary an... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutica... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of ophthalmic
diseases and disorders; pharmaceutic... |
|
|
Invention
|
Factor xiia inhibitors.
The present invention provides compounds of formula (I): compositions co... |
|
|
Invention
|
Factor xiia inhibitors. The present invention provides compounds of formula (I): compositions com... |
|
|
Invention
|
Treatments of hereditary angioedema.
The present invention relates to treatments of hereditary a... |
|
|
Invention
|
Inhibitors of plasma kallikrein.
The present invention provides compounds of formula (I),
The ... |
|
2021
|
Invention
|
Enzyme inhibitors.
The present invention provides compounds of formula (I): compositions compris... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I): compositions comprisi... |
|
|
Invention
|
Treatments of angioedema.
The present invention relates to treatments of bradykinin-mediated ang... |
|
|
Invention
|
Treatments of angioedema. The present invention relates to treatments of bradykinin-mediated angi... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I):
compositions compri... |
|
|
Invention
|
Enzyme inhibitors.
The present invention provides a selection of compounds of formula (I):
The... |
|
2020
|
Invention
|
Treatments of diabetic macular edema and impaired visual acuity.
The present invention relates t... |
|
|
Invention
|
Treatments of diabetic macular edema and impaired visual acuity. The present invention relates to... |
|
|
Invention
|
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors. The present inven... |
|
|
Invention
|
Treatments of angioedema.
The present invention relates to treatments of angioedema, and specifi... |
|
|
Invention
|
Treatments of angioedema. The present invention relates to treatments of angioedema, and specific... |
|
|
Invention
|
Enzyme inhibitors.
The present invention provides compounds of formula (I) compositions comprisi... |
|
|
Invention
|
Enzyme inhibitors.
The present invention provides compounds of formula (I) or (Ia) compositions ... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I) or (Ia) compositions c... |
|
2019
|
Invention
|
Enzyme inhibitors.
The present invention provides compounds of formula (I): Formula (I) composit... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I): Formula (I) compositi... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I) compositions comprisin... |
|
|
Invention
|
Enzyme inhibitors. The present invention provides compounds of formula (I) or (Ia): compositions ... |
|
|
Invention
|
Plasma kallikrein inhibitors. The present invention provides compounds of formula (I): (I) compos... |
|
2018
|
Invention
|
Solid forms of a plasma kallikrein inhibitor and salts thereof. New solid forms of the plasma kal... |
|
|
Invention
|
Solid forms of a plasma kallikrein inhibitor and salts thereof.
The present invention relates to... |
|
|
Invention
|
Dosage forms comprising a plasma kallikrein inhibitor. The present invention relates to oral soli... |
|
2017
|
Invention
|
Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1yl... |
